(Q30472878)

21 June 2017

1 reference

title

Helicobacter pylori: rational management options (English)

1 reference

Helicobacter pylori infectious disease

21 June 2017

0 references

1 reference

Peura D

1

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

American Journal of Medicine

21 June 2017

published in

1 reference

21 June 2017

volume

105

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

424-430

1 reference

The role of Helicobacter pylori in acid-peptic disease.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Eradication of Helicobacter pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Treatment of peptic ulcers caused by Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Role of Helicobacter pylori in Duodenal Ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Testing for Helicobacter pylori in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Eradication of Helicobacter pylori: an objective assessment of current therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

The Treatment ofHelicobacter pyloriInfection in the Management of Peptic Ulcer Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

Antimicrobial management of Helicobacter pylori-associated gastrointestinal tract disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Factors influencing the eradication of Helicobacter pylori with triple therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900297-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00297-6

1 reference

21 June 2017

1 reference